Terumo BCT automates TIL production
Terumo Blood and Cell Technologies partners with TrAMPoline Pharma and the University of Colorado to use the Quantum Flex™ Cell Expansion System for automated TIL manufacturing. The goal is to bridge the gap between lab development and clinical scale while preserving product quality.
- Field
- gene therapy
- What they did
- Terumo BCT, in partnership with TrAMPoline Pharma and the University of Colorado, is developing an automated system to manufacture genetically engineered Tumor-Infiltrating Lymphocytes (TILs) for cancer treatment.
- Why it matters
- Automation is intended to bridge the gap between laboratory development and clinical scale by using scalable technology for both phases, thereby preserving product quality throughout the development pipeline.
#til#cell therapy#automation#terumo bct#gene editing



